Twist Bioscience Corporation
Twist Bioscience Corporation is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in South San Francisco, CA. Its latest filed balance sheet (2025-09-30) shows total assets of $676 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2836), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.1 out of ten, 8 of 9 metrics filed and 1 estimated: past 6.8 out of ten, present 7.6 out of ten, future 4.4 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 5.8 out of ten. 1 warning event since 2017; the latest 2022-03-09. 58th percentile among 159 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 7.3 out of ten. +55.9% a year over 9 filed years; profitable in 0 of 9. 73rd percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 6.8 out of ten. CrossAssetData estimate 6.8/10, confidence 35 of 100 (one part). 67th percentile among 146 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
- Financial health (present): 7.3 out of ten. ROE -16%: lost 16¢ per shareholder dollar. Leverage 26%: owes 26¢ per asset dollar. 73rd percentile among 147 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 7.4 out of ten. top 26% of 102 in its family; net margin -20.6%. 74th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 8.1 out of ten. top 19% of 108 in its family for leadership; chief executive since 2018. 81st percentile among 108 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 4.3 out of ten. bottom 44% of 92 in its family for room to expand. 44th percentile among 92 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 3.8 out of ten. bottom 38% of 100 in its family for growth drivers. 38th percentile among 100 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 5.7 out of ten. top 43% of 72 in its family for expectations against reality. 57th percentile among 72 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2025-11-17 for the period ended 2025-09-30 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-03 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-03 (on EDGAR). Newest filing: Form 144, 2026-10-09. Filings on record since 2013. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Ngs Tools 55%, Synthetic Genes 30%, Antibody Discovery 6%, Oligo Pools 5%, Dna and Biopharma Libraries 3%. By geography: Americas 60%, EMEA 33%, APAC 7%. As tagged in its annual report (Form 10-K, filed 2025-11-17).
Who runs it
Leproust, Emily M. (Chief Executive Officer); Finn, Patrick John (President and COO); Laponis, Adam (Chief Financial Officer); Werner, Robert F. (Chief Accounting Officer); Green, Paula (SVP of Human Resources); Cho, Dennis (See Remarks); Blake, Katryn (director); Chess, Robert (director); Starovasnik, Melissa A. (director); Johannessen, Jan (director); and 3 more. 13 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-07.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.